As part of one of the world’s top industries, pharmaceutical companies bring in billions of dollars and save millions of lives. Time and money goes into the process of research and development, drug discovery, and bioprocessing – the necessary parts of getting drugs with life-saving potential to market. Eliminating potential pitfalls and saving time where possible while not decreasing quality is essential for biotherapeutics. Many product candidates will not be selected for commercial development but still need to be manufactured appropriately for preclinical and clinical testing.
In terms of bioprocessing, scientists have found that modifying current mammalian expression platforms could be the answer. Of these platforms, Chinese hamster ovary (CHO) cells are most commonly used.
According to a review on how CHO cells are used in bioprocessing by Fan et al., CHO cells are used in more than half of approved therapeutic proteins due to their robust growth that fairs nicely in producing large-scale pharmaceuticals.1 Possessing the ability for human-like post-translational modifications is an added benefit as this is typically necessary in biotherapeutic development.
One drawback to using CHO cells is the clonal selection process. This is the rate-limiting step in bioprocessing since it takes a lot of time and money to ensure pools or single clones with high and stable expression of an intended biologic are selected out of all the transfected cells.
Conversely, targeting GS with gene editing technology to obtain a full phenotypic knockout (zero GS protein expression) is far more effective compared to the typical GS MSX inhibition system. GS knockout cells allow for faster and more complete cell line selection and overall reduce the cell line development timeline.1
Novel gene editing proteins – such as Cas-CLOVER – target specific genes in a deliberate manner. This is compared to the older, labor-intensive processes of random insertion, sequential homologous recombination, or causing a frameshift in many genomic sites with the hopes that a mutation will occur in the target sequence.
Combining newer gene editing tools that have specific targeting capabilities with robust CHO expression systems has significantly impacted bulk cell culture productivity. As demonstrated in the figure below from Fan et al., GS KO cells (edited with relatively low efficiency with zinc-finger nuclease), yield an increased rate of high-producing cells resulting in improved efficiency.1
Demeetra’s proprietary Cas-CLOVER utilizes guide RNA targeting with an ultraspecific dimeric nuclease Clo051. In our system, dCas serves as a fusion protein only. It is mutated and unable to cut DNA. As opposed to the use of a single guide RNA (gRNA) like that in CRISPR, the Cas-CLOVER system utilizes two gRNAs in addition to the Clo051 nuclease activity that requires dimerization of subunits associated with each guide RNA. Using two gRNA makes the Cas-CLOVER gene editing system highly targeted and only functional when the paired gRNAs dimerize at the correct target site.
Cas-CLOVER requires two gRNA and “PAM” (NGG) target sites. But fortunately, the number of nucleotides allowable for Clo051 function between the two gRNAs – the “spacer region” – is relatively large and flexible. Leveraging Cas-CLOVER’s flexible design, high efficiency and precision we set out to establish genome edited suspension CHO cell products.
Multiplexing by co-transfection of two gRNA pairs with Cas-CLOVER resulted in 196 base-pair deletion, eliminating nearly an entire exon of the GS gene. These large deletions resulted in single-cell clones that had a full GS knockout phenotype as shown by complete loss of viability without glutamate media supplementation.
Furthermore, Cas-CLOVER mediated GS knockout CHO cell viability was recovered when the GS gene was stably transformed. Cultures in the figure were kept under +/- Glutamine conditions for 19 days.
Reach out to us to learn more by contacting us here.
Fan, L., Frye, C. C., & Racher, A. J. (2013). The use of glutamine synthetase as a selection marker: recent advances in Chinese hamster ovary cell line generation processes. Pharmaceutical Bioprocessing, 1 (5), 487–502. https://www.openaccessjournals.com/articles/the-use-of-glutamine-synthetase-as-a-selection-marker-recent-advances-in-chinese-hamster-ovary-cell-line-generation-proc.pdf